Source:http://linkedlifedata.com/resource/pubmed/id/18950458
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2008-11-27
|
| pubmed:abstractText |
This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years. Three hundred and one AML patients were randomized to receive DNR (45 mg/m(2) days 1-3) or DNX (80 mg/m(2) days 1-3) plus cytarabine (AraC; 100 mg/m(2) days 1-7). Patients in complete remission (CR) received a course of the same drugs as consolidation and then were randomized for maintenance with AraC+ all trans retinoic acid or no further treatment. Among 153 patients in the DNR arm, 78 (51.0%) achieved CR, 55 (35.9%) were resistant and 20 (13.1%) died during induction. Among 148 patients in the DNX arm, 73 (49.3%) achieved CR, 47 (31.8%) were resistant and 28 (18.9%) died during induction. Univariate analysis showed no difference as to induction results. After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis. DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1365-2141
|
| pubmed:author |
pubmed-author:AlimenaGiulianaG,
pubmed-author:AmadoriSergioS,
pubmed-author:BaccaraniMicheleM,
pubmed-author:BrecciaMassimoM,
pubmed-author:CandoniAnnaA,
pubmed-author:CaramattiCeciliaC,
pubmed-author:Di RaimondoFrancescoF,
pubmed-author:FabbianoFrancescoF,
pubmed-author:FalzettiFrancaF,
pubmed-author:FaziPaolaP,
pubmed-author:IacobelliSimonaS,
pubmed-author:LatagliataRobertoR,
pubmed-author:MandelliFrancoF,
pubmed-author:MartinelliGiovanniG,
pubmed-author:MatteiDanieleD,
pubmed-author:MorselliMonicaM,
pubmed-author:PirrottaMaria TeresaMT,
pubmed-author:SborgiaMarcoM,
pubmed-author:VignettiMarcoM,
pubmed-author:ZaccariaAlfonsoA
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
143
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
681-9
|
| pubmed:dateRevised |
2009-2-23
|
| pubmed:meshHeading |
pubmed-meshheading:18950458-Aged,
pubmed-meshheading:18950458-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18950458-Daunorubicin,
pubmed-meshheading:18950458-Disease-Free Survival,
pubmed-meshheading:18950458-Female,
pubmed-meshheading:18950458-Follow-Up Studies,
pubmed-meshheading:18950458-Humans,
pubmed-meshheading:18950458-Leukemia, Myeloid, Acute,
pubmed-meshheading:18950458-Liposomes,
pubmed-meshheading:18950458-Male,
pubmed-meshheading:18950458-Middle Aged,
pubmed-meshheading:18950458-Proportional Hazards Models,
pubmed-meshheading:18950458-Recurrence,
pubmed-meshheading:18950458-Remission Induction,
pubmed-meshheading:18950458-Survival Rate,
pubmed-meshheading:18950458-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
|
| pubmed:affiliation |
Ematologia, Università La Sapienza, Rome, Italy. rob.lati@libero.it
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III
|